Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly vs twice-weekly intralesional meglumine antimoniate for cutaneous leishmaniasis caused by L. tropica
IRCT20081130001475N13Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Complete cure. Started Oct 2017; status: completed.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20081130001475N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20081130001475N13.